健帆生物
(300529)
| 流通市值：77.99亿 | | | 总市值：121.55亿 |
| 流通股本：5.12亿 | | | 总股本：7.99亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 1,032,473,665.31 | 560,623,604.23 | 2,011,817,980.59 | 1,556,021,993.54 |
| 营业总成本 | 596,082,381.08 | 307,800,952.25 | 1,338,531,874.32 | 1,020,308,100.76 |
| 其他经营收益 | | | | |
| 营业利润 | 452,054,661.47 | 261,216,188.99 | 690,786,476.63 | 586,380,633.08 |
| 利润总额 | 447,133,271.08 | 260,014,653.23 | 660,127,097.16 | 552,053,862.95 |
| 净利润 | 382,988,907.47 | 220,647,736.37 | 531,671,178.89 | 451,858,349.46 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | 2,799,145.61 | - |
| 综合收益总额 | 382,988,907.47 | 220,647,736.37 | 534,470,324.5 | 451,858,349.46 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 2,788,915,186.46 | 3,034,437,075.2 | 2,917,973,577.81 | 2,915,854,287.4 |
| 非流动资产: | | | | |
| 非流动资产合计 | 2,406,863,399.79 | 2,486,794,577.61 | 2,490,980,424.15 | 2,620,246,316.85 |
| 资产总计 | 5,195,778,586.25 | 5,521,231,652.81 | 5,408,954,001.96 | 5,536,100,604.25 |
| 流动负债: | | | | |
| 流动负债合计 | 1,322,300,637.76 | 348,560,141.09 | 502,096,990.91 | 685,205,805.61 |
| 非流动负债: | | | | |
| 非流动负债合计 | 414,292,732.59 | 1,473,158,938.31 | 1,435,531,590.7 | 1,422,240,153.75 |
| 负债合计 | 1,736,593,370.35 | 1,821,719,079.4 | 1,937,628,581.61 | 2,107,445,959.36 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 3,458,557,129.22 | 3,699,769,529.76 | 3,471,717,243.94 | 3,429,268,141.05 |
| 股东权益合计 | 3,459,185,215.9 | 3,699,512,573.41 | 3,471,325,420.35 | 3,428,654,644.89 |
| 负债和股东权益合计 | 5,195,778,586.25 | 5,521,231,652.81 | 5,408,954,001.96 | 5,536,100,604.25 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,141,934,047.62 | 614,887,721.65 | 2,459,988,549.01 | 1,865,890,761.17 |
| 经营活动现金流出小计 | 730,722,855.71 | 358,996,312.79 | 1,738,772,105.82 | 1,292,650,606 |
| 经营活动产生的现金流量净额 | 411,211,191.91 | 255,891,408.86 | 721,216,443.19 | 573,240,155.17 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,606,582,005.67 | 1,027,451,350.09 | 4,590,744,142.13 | 1,930,802,969.43 |
| 投资活动现金流出小计 | 3,460,423,268.65 | 3,224,024,768.32 | 3,947,590,825.89 | 3,173,223,187.59 |
| 投资活动产生的现金流量净额 | -1,853,841,262.98 | -2,196,573,418.23 | 643,153,316.24 | -1,242,420,218.16 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 45,857,957.68 | 31,107,959.86 | 1,233,378,827.84 | 528,230,606.2 |
| 筹资活动现金流出小计 | 585,901,618.79 | 114,685,729.97 | 1,796,710,684.18 | 1,124,700,280.94 |
| 筹资活动产生的现金流量净额 | -540,043,661.11 | -83,577,770.11 | -563,331,856.34 | -596,469,674.74 |
| 汇率变动对现金及现金等价物的影响 | -3,893,588.93 | -1,821,163.03 | -1,722,510.72 | -525,067.85 |
| 现金及现金等价物净增加额 | -1,986,567,321.11 | -2,026,080,942.51 | 799,315,392.37 | -1,266,174,805.58 |
| 期末现金及现金等价物余额 | 488,414,312.51 | 448,900,691.11 | 2,474,981,633.62 | 409,491,435.67 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -1,986,567,321.11 | - | 799,315,392.37 | - |
最新报告期：2026-08-06| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 国金证券 | 何冠洲,甘坛焕 | 0.77 | 0.88 | 1.02 | 2026-08-06 |
| 华泰证券 | 代雯,高鹏 | 0.81 | 0.90 | 0.99 | 2026-08-06 |